Browse >
Home / Archive: July 2008
The Lymphoma Association, the only specialist UK charity that provides medical information and support to lymphatic cancer patients, their families and friends, is calling for nominations for their annual Beacons of Hope Awards. As Julie Mercer, Head of Communications for the charity says: "The awards are part of the activities for World Lymphoma Awareness Day - which is celebrated annually on September 15.
UroToday.com - In the online version of Urology, Dr. James McKiernan and a group of investigators at Columbia University reported that while clinical subgroups of stage cT2 prostate cancer (CaP) have prognostic significance, pathologic subgroups of stage pT2 do not. In 1997, the American Joint Committee on Cancer (AJCC) eliminated the stage cT2 sub-staging, based upon the degree of prostatic lobar involvement. T2a was classified as unilobar, and T2 as bilobar disease.
One-fifth of British adult survivors of childhood cancers are current smokers, and nearly a third have been regular smokers at some point in their lives, according to a study in the July 29 online issue of the Journal of the National Cancer Institute. Adult survivors of childhood cancer are at increased risk of developing cardiovascular disease, lung problems, and second malignancies, relative to the general public.
UroToday.com - In the August 2008 issue of the Journal of Urology, Dr. Ian Thompson and colleagues explored the performance characteristics of PSA after a previous negative prostate biopsy. The population of men had all undergone prostate biopsy regardless of PSA or digital rectal examination (DRE) findings, thus minimizing the confounding effects of verification bias.
UroToday.com - In an article by a group of French investigators that appears in the online version of European Urology, they examine the issue of whether one negative extended prostate cancer (CaP) biopsy should reassure patients that they do not have CaP. Between 2001 and 2007, 953 men had initial negative extended prostate biopsies, and 231 underwent at least one more set of 21-core biopsies.
The Same Dose of Anthracycline Is Not Safe for Everyone Not all patients can tolerate the currently recommended cumulative dose of epirubicin. New models can help physicians calculate the epirubicin dose associated with a 5 percent risk of cardiotoxicity for individual patients. Oncologists frequently use anthracyclines, including epirubicin and doxorubicin, to treat breast cancer patients.
UroToday.com - Previous animal studies suggested a role for estrogens in the pathogenesis of benign prostatic hyperplasia (BPH) 1,2. Estrogens interact with two forms of estrogen receptor (ER), ERα and ERβ. We recently reported the differential expression of the two ER subtypes in stromal and epithelial cells derived from human BPH tissues 3.
A patient with pancreatic cancer recently became the first person in the United States to receive treatment using Elekta VMAT (Volumetric intensity Modulated Arc Therapy) at Seattle's Swedish Cancer Institute. This revolutionary new technology dramatically decreases treatment times -- delivering a higher dose to the tumor target without compromising coverage and patient safety.
UroToday.com - Standard front-line cisplatin-based combination chemotherapy for metastatic transitional cell carcinoma (TCC) with either MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) or GC (gemcitabine, cisplatin) yields a median survival of approximately 15 months. The response rate with these regimens is 40-60% and subsequent progression is almost universal, with salvage chemotherapy being relatively ineffective.
Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the growth of breast cancer cells that migrate to the brain. The small molecule used in the studies was the drug lapatinib (Tykerb®), which disrupts an important breast cancer metabolic process called the Her2/neu signaling pathway.
Next Page »
